+1 347 583 0215 (Text) info@uberevents.io
Event programme

2027 CRBE Summit West

2027 CRBE Summit West: Innovations in Controlled Release, Bioavailability Enhancement & Biologics Drug Delivery Systems

February 23–24, 2027 Hilton La Jolla Torrey Pines, San Diego, CA
Preliminary programme · Subject to change

2027 CRBE Summit West

Draft agenda preview · February 23–24, 2027 · Hilton La Jolla Torrey Pines · Times Pacific (PT)

8:00 AMto 9:00 AM PT
Registration Opens & Continental Breakfast for Attendees
8:55 AMto 9:00 AM PT
Welcome and Chairperson's Introduction & Opening Remarks
Keynotes
9:00 AMto 9:40 AM PT
Keynote: AI-driven formulation development (title pending)
KeynoteProvisional title
Christine Allen, PhD
Christine Allen, PhD
Professor, Leslie Dan Faculty of Pharmacy · Co-founder & CEO, Intrepid Labs · University of Toronto
9:40 AMto 10:20 AM PT
Mesoporous Silicon in Degradable Drug Delivery Systems
KeynoteConfirmed title
Michael J. Sailor, PhD
Michael J. Sailor, PhD
Distinguished Professor, Chemistry & Biochemistry · UC San Diego
AI / ML & formulation
10:20 AMto 10:50 AM PT
Collaborative AI/ML drug discovery for small molecules and antibodies (Tue Feb 23; title pending)
Provisional title
Vanessa Braunstein, PhD
Vanessa Braunstein, PhD
Sr. Director, TuneLab AI Drug Discovery Platform · Eli Lilly and Company
10:50 AMto 11:20 AM PT
Optimization of formulation and process design parameter space: A Resource-Efficient ML Approach
Fady Ibrahim, PhD
Fady Ibrahim, PhD
Head of Global Biopharmaceutics and USA Drug Product Development · Sanofi
11:20 AMto 11:50 AM PT
Morning Networking Break in Exhibit Hall
Preclinical & biopharmaceutics
11:50 AMto 12:20 PM PT
Fail Fast, Formulate Smart: Preclinical Formulation Strategies That De-Risk Early Development
Peter Wuelfing, PhD
Peter Wuelfing, PhD
Executive Director, Pharmaceutical Sciences · Merck
12:20 PMto 12:50 PM PT
Panel TBC (preferred topic: Biopharmaceutics: BCS, IVIVC and regulatory considerations for small molecule dosage forms)
Tao Wu, PhD
Tao Wu, PhD
Executive Director and Head of CMC · Kumquat Biosciences
12:50 PMto 2:00 PM PT
Networking Lunch
Long-acting injectables
2:00 PMto 2:30 PM PT
From Concept to IND in 18 Months: CMC Strategy for Long-Acting Injectables at a Lean Biotech
Chong-Hui Gu, PhD
Chong-Hui Gu, PhD
Senior Vice President, CMC & Supply Chain · Tenvie Therapeutics
2:30 PMto 3:00 PM PT
Bioperformance Considerations for Long-Acting Injectable (LAI) Product Development
Simone Alidori, PhD
Simone Alidori, PhD
Director, Biopharmaceutics · Merck
3:00 PMto 3:30 PM PT
In vitro and in silico testing methods for controlled release in-situ forming gels/injectables (Pion; also exhibitor)
Provisional title
Immy Anastasiou
Immy Anastasiou
Senior Product Manager · Pion, Inc.
Long-acting injectables & in-situ systems
4:00 PMto 4:20 PM PT
Afternoon Networking Break in Exhibit Hall
Device & combination products
4:20 PMto 4:50 PM PT
Novel, Impact-free, Swappable-payload Microneedle Delivery for Global Health
Tycho Speaker, PhD
Tycho Speaker, PhD
Senior Principal Research Scientist, Combination Product Development & Drug Delivery · AbbVie
Device & combination-product delivery
5:20 PMto 5:30 PM PT
Chair's Closing Remarks, Drinks Reception in Exhibit Hall and End of Day One
9:00 AMto 9:05 AM PT
Chairperson's Welcome & Opening Remarks
Keynotes
9:05 AMto 9:45 AM PT
Keynote: From Needle to Pill: How Oral Peptides Are Rewriting Drug Delivery
KeynoteProvisional title
Stephen Buckley, PhD
Stephen Buckley, PhD
Vice President, Head of Oral Delivery Technologies · Novo Nordisk
Oral peptides & biologics
9:45 AMto 10:15 AM PT
Deconvoluting the Impact of Peptide Solution Behavior on Oral Absorption with Sodium
Tahnee Dening, PhD
Tahnee Dening, PhD
Principal Scientist, Discovery Pharmaceutics · Genentech
10:15 AMto 10:45 AM PT
POD: Bringing biologics out of the syringe and into the capsule
Miriam Kidron, PhD
Miriam Kidron, PhD
Chief Scientific Officer · Oramed Pharmaceuticals
10:45 AMto 11:15 AM PT
Morning Networking Break in Exhibit Hall
Oral peptides & biologics
11:15 AMto 11:45 AM PT
Integrating AI with Patented Peptide Delivery Platforms for Therapeutics and Longevity Applications
Confirmed title
Norman Lai, PhD
Norman Lai, PhD
CTO · Ibex Bioscience / USMediGene
High-concentration SC delivery
11:45 AMto 12:15 PM PT
Advancements in High-concentration, High-Dose Formulations for SC Administration of Protein Therapeutics
Anna Putnam, PhD
Anna Putnam, PhD
President, Aerocon Division · Halozyme
12:15 PMto 12:45 PM PT
IV to Subcutaneous Injection: Enabling High-Dose Monoclonal Antibody Delivery
Sasha Ebrahimi, PhD
Sasha Ebrahimi, PhD
Scientific Leader, Emerging Drug Delivery Platforms · GlaxoSmithKline
12:45 PMto 1:45 PM PT
Networking Lunch
Nucleic acids & mRNA
1:45 PMto 2:15 PM PT
The Great Escape, Part II: Engineering Smarter Intracellular Delivery of Nucleic Acids
Provisional title
Ismail Hafez, PhD
Ismail Hafez, PhD
Director, Formulation and Delivery Sciences, Gene-Editing · Ionis Pharmaceuticals
2:15 PMto 2:45 PM PT
Biodistribution of mRNA Vaccines (working title)
Yun Liu, PhD
Yun Liu, PhD
DMPK Project Representative · Moderna
2:45 PMto 3:00 PM PT
Networking Break in Exhibit Hall
Nasal delivery
3:00 PMto 3:30 PM PT
Nasal Delivery Reimagined: A Scalable Platform for Systemic and Nose-to-Brain Therapies
Confirmed title
Deb Das, PhD
Deb Das, PhD
Sr. Assoc. Director & Fellow, New Product Development & CMC Lead · Bayer
Advanced / alternative delivery (post nucleic & nasal)
Partnering
4:00 PMto 4:30 PM PT
Panel 1: The Next Deal: What Pharma Wants to Partner On in Delivery Tech
Sarah Tao, PhD
Sarah Tao, PhD
Senior Director, Search & Evaluation; Immunoglobulin Therapeutic Area & Technologies Lead · CSL Behring
Partnering & closing block
5:00 PMto 5:10 PM PT
Chair's Closing Remarks and End of Day Two
5:10 PMto 6:00 PM PT
Networking / Social Gathering (venue TBC)
Confirmed speaker — session and timing TBD

Kept out of the timed thematic sequence until a session slot is chosen. Four open sponsor placeholders remain unchanged.

TBDPacific
Session TBD
Session & timing TBD
Michael Morgen
Michael Morgen
Director, R&D · Lonza
Confirmed speaker — session and timing TBD. Not placed in the timed day grid yet. Four open sponsor slots stay reserved separately.